Ahmed A Othman

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 52

Top Venues

Journal of clinical pharmacology

Clinical pharmacokinetics

Clinical and translational science

Clinical pharmacology and therapeutics

Gilead Sciences

University of Maryland Baltimore (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Gilead Sciences

United States

Executive Director :: Clinical Pharmacology

AbbVie Inc

United States

Senior Director and Research Fellow :: Clinical Pharmacology and Pharmacometrics

Education History

University of Maryland Baltimore

United States

PHD :: Pharmaceutical Sciences

Cairo University Faculty of Pharmacy

Egypt

BSC :: Pharmaceutical Sciences

Publications

Elijah J Weber, Islam R Younis, Cara Nelson, Ann R Qin, Timothy R Watkins, Ahmed A Othman
Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Firsocostat, a Liver-Targeted Inhibitor of Acetyl-CoA Carboxylase. Clinical pharmacokinetics (2024)
Jared M Odegard, Ahmed A Othman, Kai-Wen Lin, Adele Y Wang, Jonathan Nazareno, Oh Kyu Yoon, John Ling, Latesh Lad, P Rod Dunbar, Dung Thai, Edmond Ang, Nicholas Waldron, Sanjeev Deva
Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (4) (2024)
Divya Samineni, Karthik Venkatakrishnan, Ahmed A Othman, Yazdi K Pithavala, Srinivasu Poondru, Chirag Patel, Pavan Vaddady, Wendy Ankrom, Saroja Ramanujan, Nageshwar Budha, Michael Wu, Nahor Haddish-Berhane, Holger Fritsch, Azher Hussain, Jitendra Kanodia, Meng Li, Mengyao Li, Murad Melhem, Apurvasena Parikh, Vijay V Upreti, Neeraj Gupta
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper. Clinical pharmacology and therapeutics 116 (3) (2024)
Islam R Younis, Cara Nelson, Elijah J Weber, Gong Shen, Ann R Qin, Deqing Xiao, Timothy R Watkins, Ahmed A Othman
Pharmacokinetics and Safety of Cilofexor and Firsocostat in Healthy Japanese and Non-Japanese Participants. Journal of clinical pharmacology (2024)
Islam R Younis, Cara Nelson, Elijah J Weber, Ann R Qin, Timothy R Watkins, Ahmed A Othman
Pharmacokinetics and Safety of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment. Journal of clinical pharmacology 64 (7) (2024)
Abhishek G Sathe, Indrajeet Singh, Pratap Singh, Paul M Diderichsen, Xiaohui Wang, Peter Chang, Atiya Taqui, See Phan, Sandhya Girish, Ahmed A Othman
Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors. Clinical pharmacokinetics 63 (5) (2024)
Islam R Younis, Fan Wang, Ahmed A Othman
Feasibility of Using Population Pharmacokinetics-Based Virtual Control Groups in Organ Impairment Studies. Journal of clinical pharmacology (2024)
Jared M Odegard, Ahmed A Othman, Kai-Wen Lin, Adele Y Wang, Jonathan Nazareno, Oh Kyu Yoon, John Ling, Latesh Lad, P Rod Dunbar, Dung Thai, Edmond Ang, Nicholas Waldron, Sanjeev Deva
Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (4) (2024)
Islam R Younis, Cara Nelson, Elijah J Weber, Ann R Qin, Timothy R Watkins, Ahmed A Othman
Pharmacokinetics and Safety of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment. Journal of clinical pharmacology (2024)
Abhishek G Sathe, Indrajeet Singh, Pratap Singh, Paul M Diderichsen, Xiaohui Wang, Peter Chang, Atiya Taqui, See Phan, Sandhya Girish, Ahmed A Othman
Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors. Clinical pharmacokinetics 63 (5) (2024)
Abhishek G Sathe, Indrajeet Singh, Pratap Singh, Paul M Diderichsen, Xiaohui Wang, Peter Chang, Atiya Taqui, See Phan, Sandhya Girish, Ahmed A Othman
Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors. Clinical pharmacokinetics 63 (5) (2024)
Abhishek G Sathe, Indrajeet Singh, Pratap Singh, Paul M Diderichsen, Xiaohui Wang, Peter Chang, Atiya Taqui, See Phan, Sandhya Girish, Ahmed A Othman
Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors. Clinical pharmacokinetics (2024)
Anees M Dauki, Nishanthan Rajakumaraswamy, Torsten Trowe, Winnie Weng, Kai-Wen Lin, Emon Elboudwarej, Ann Ran-Ran Qin, Christian Schwabe, Michelle R Kuhne, Ahmed A Othman
Pharmacokinetics, pharmacodynamics, and safety of GS-3583, a FLT3 agonist Fc fusion protein, from single-ascending-dose phase I study in healthy participants. Clinical and translational science 17 (8) (2024)
Anees M Dauki, Nishanthan Rajakumaraswamy, Torsten Trowe, Winnie Weng, Kai-Wen Lin, Emon Elboudwarej, Ann Ran-Ran Qin, Christian Schwabe, Michelle R Kuhne, Ahmed A Othman
Pharmacokinetics, pharmacodynamics, and safety of GS-3583, a FLT3 agonist Fc fusion protein, from single-ascending-dose phase I study in healthy participants. Clinical and translational science 17 (8) (2024)
Islam R Younis, Cara Nelson, Elijah J Weber, Ann R Qin, Timothy R Watkins, Ahmed A Othman
Pharmacokinetics and Safety of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment. Journal of clinical pharmacology 64 (7) (2024)
Jared M Odegard, Ahmed A Othman, Kai-Wen Lin, Adele Y Wang, Jonathan Nazareno, Oh Kyu Yoon, John Ling, Latesh Lad, P Rod Dunbar, Dung Thai, Edmond Ang, Nicholas Waldron, Sanjeev Deva
Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (4) (2024)
Islam R Younis, Fan Wang, Ahmed A Othman
Feasibility of Using Population Pharmacokinetics-Based Virtual Control Groups in Organ Impairment Studies. Journal of clinical pharmacology 64 (6) (2024)
Divya Samineni, Karthik Venkatakrishnan, Ahmed A Othman, Yazdi K Pithavala, Srinivasu Poondru, Chirag Patel, Pavan Vaddady, Wendy Ankrom, Saroja Ramanujan, Nageshwar Budha, Michael Wu, Nahor Haddish-Berhane, Holger Fritsch, Azher Hussain, Jitendra Kanodia, Meng Li, Mengyao Li, Murad Melhem, Apurvasena Parikh, Vijay V Upreti, Neeraj Gupta
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper. Clinical pharmacology and therapeutics (2024)
Jared M Odegard, Ahmed A Othman, Kai-Wen Lin, Adele Y Wang, Jonathan Nazareno, Oh Kyu Yoon, John Ling, Latesh Lad, P Rod Dunbar, Dung Thai, Edmond Ang, Nicholas Waldron, Sanjeev Deva
Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (4) (2024)
Abhishek G Sathe, Indrajeet Singh, Pratap Singh, Paul M Diderichsen, Xiaohui Wang, Peter Chang, Atiya Taqui, See Phan, Sandhya Girish, Ahmed A Othman
Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors. Clinical pharmacokinetics 63 (5) (2024)
Elijah Weber, Islam R Younis, Cara Nelson, Dora Ding, Ann Qin, Deqing Xiao, Timothy R Watkins, Ahmed A Othman
Effect of Renal Impairment on the Pharmacokinetics of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist. Journal of clinical pharmacology (2023)
Elijah Weber, Islam Younis, Cara Nelson, Dora Ding, Ann Qin, Deqing Xiao, Timothy R Watkins, Ahmed A Othman
Effect of Renal Impairment on the Pharmacokinetics of Firsocostat, an Acetyl-CoA Carboxylase (ACC) Inhibitor, and Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist. Journal of clinical pharmacology (2023)
Islam R Younis, Brian J Kirby, Andrew N Billin, Deqing Xiao, Qinghua Song, Timothy R Watkins, Ahmed A Othman
Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers. Clinical and translational science 16 (3) (2023)
Islam Younis, Elijah Weber, Cara Nelson, Brian J Kirby, Gong Shen, Deqing Xiao, Timothy R Watkins, Ahmed A Othman
Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist. Clinical pharmacokinetics (2023)
Islam R Younis, Brian J Kirby, Andrew N Billin, Deqing Xiao, Qinghua Song, Timothy R Watkins, Ahmed A Othman
Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers. Clinical and translational science 16 (3) (2023)
Islam R Younis, Brian J Kirby, Andrew N Billin, Deqing Xiao, Qinghua Song, Timothy R Watkins, Ahmed A Othman
Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers. Clinical and translational science (2022)
Anees M Dauki, Chia-Hsiang Hsueh, Ganesh Cherala, Ahmed A Othman
Oral Glucose Tolerance Test: An Informative Endpoint or an Added Burden in Metformin Drug-Drug Interaction Studies? Clinical pharmacology and therapeutics 112 (3) (2022)
Ganesh Cherala, Cara Nelson, Ying Guo, Anubhav Mathur, Thomas Tarnowski, Ahmed A Othman
Evaluation of the potential for pharmacokinetic interaction between tirabrutinib and levonorgestrel/ethinyl estradiol in healthy female volunteers. Clinical and translational science 15 (6) (2022)
Islam R Younis, Brian J Kirby, Andrew N Billin, Deqing Xiao, Qinghua Song, Timothy Watkins, Ahmed A Othman
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Cilofexor, a Novel Nonsteroidal Farnesoid X Receptor Agonist, in Healthy Volunteers. Clinical and translational science (2022)
Mohamed-Eslam F Mohamed, Ben Klünder, Ahmed A Othman
Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication. Clinical pharmacokinetics 59 (5) (2021)
Chia-Hsiang Hsueh, Kacey Anderson, Gong Shen, Chohee Yun, Ann Qin, Ahmed A Othman
Evaluation of the potential drug interactions mediated through P-gp, OCT2, and MATE1/2K with filgotinib in healthy subjects. Clinical and translational science (2021)
Ahmed Nader, Mukul Minocha, Ahmed A Othman
Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus. Clinical pharmacokinetics 59 (3) (2021)
Ahmed A Suleiman, Amit Khatri, Rajneet K Oberoi, Ahmed A Othman
Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis. Clinical pharmacokinetics 59 (5) (2021)
Yinuo Pang, Amit Khatri, Ahmed A Suleiman, Ahmed A Othman
Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients. Clinical pharmacokinetics 59 (3) (2021)
Abhishek G Sathe, Ahmed A Othman, Mohamed-Eslam F Mohamed
Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates. Journal of clinical pharmacology 61 (3) (2020)
Ben Klünder, Rajendar K Mittapalli, Mohamed-Eslam F Mohamed, Anna Friedel, Peter Noertersheuser, Ahmed A Othman
Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials. Clinical pharmacokinetics 58 (8) (2020)
Ahmed A Suleiman, Mukul Minocha, Amit Khatri, Yinuo Pang, Ahmed A Othman
Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials. Clinical pharmacokinetics 58 (10) (2020)
Mohamed-Eslam F Mohamed, Sathej Gopalakrishnan, Henrique D Teixeira, Ahmed A Othman
Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses. Journal of clinical pharmacology 61 (5) (2020)
Mohamed-Eslam F Mohamed, Tian Feng, Jeffrey V Enejosa, Ogert Fisniku, Ahmed A Othman
Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail. Journal of clinical pharmacology 60 (1) (2019)
Mohamed-Eslam F Mohamed, Ben Klünder, Heidi S Camp, Ahmed A Othman
Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection. Clinical pharmacology and therapeutics 106 (6) (2019)
Amit Khatri, Doerthe Eckert, Rajneet Oberoi, Ahmed Suleiman, Yinuo Pang, Ling Cheng, Ahmed A Othman
Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis. Journal of clinical pharmacology 59 (12) (2019)
Roy M Fleischmann, Aileen L Pangan, In-Ho Song, Eduardo Mysler, Louis Bessette, Charles Peterfy, Patrick Durez, Andrew J Ostor, Yihan Li, Yijie Zhou, Ahmed A Othman, Mark C Genovese
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.) 71 (11) (2019)
Sheryl Trueman, Mohamed-Eslam F Mohamed, Tian Feng, Ana Paula Lacerda, Thomas Marbury, Ahmed A Othman
Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics. Journal of clinical pharmacology 59 (9) (2019)
Ahmed Nader, Sven Stodtmann, Anna Friedel, Mohamed-Eslam F Mohamed, Ahmed A Othman
Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials. Journal of clinical pharmacology 60 (4) (2019)
Han Witjes, Amit Khatri, Paul Matthias Diderichsen, Jaap Mandema, Ahmed A Othman
Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority. Clinical pharmacology and therapeutics 107 (2) (2019)
Amit Khatri, Ahmed A Suleiman, Akshanth R Polepally, Ahmed A Othman
Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients. Clinical pharmacology and therapeutics 107 (2) (2019)
Mohamed-Eslam F Mohamed, Denise Beck, Heidi S Camp, Ahmed A Othman
Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib. Journal of clinical pharmacology 60 (2) (2019)
Mohamed-Eslam F Mohamed, Sheryl Trueman, Tian Feng, Jaclyn Anderson, Thomas C Marbury, Ahmed A Othman
Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics. Journal of clinical pharmacology 59 (6) (2019)
Mohamed-Eslam F Mohamed, Ben Klünder, Ana P Lacerda, Ahmed A Othman
Exposure-Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended-Release Formulation. Clinical pharmacology and therapeutics 107 (3) (2019)
Earle E Bain, Laura Shafner, David P Walling, Ahmed A Othman, Christy Chuang-Stein, John Hinkle, Adam Hanina
Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia. JMIR mHealth and uHealth 5 (2) (2017)
Mohamed-Eslam F Mohamed, Jiewei Zeng, Ping Jiang, Balakrishna Hosmane, Ahmed A Othman
Use of Early Clinical Trial Data to Support Thorough QT Study Waiver for Upadacitinib and Utility of Food Effect to Demonstrate ECG Assay Sensitivity. Clinical pharmacology and therapeutics 103 (5) (2017)
Mohamed-Eslam F Mohamed, Steven Jungerwirth, Armen Asatryan, Ping Jiang, Ahmed A Othman
Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. British journal of clinical pharmacology 83 (10) (2017)

Ahmed A Othman.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Ahmed A Othman